false
Catalog
Metabolic Comorbidity in Severe Mental Illness: Tr ...
Presentation Slides
Presentation Slides
Back to course
Pdf Summary
The document titled "Metabolic Comorbidity in Severe Mental Illness: Treating the Brain While Minding the Body" discusses the high prevalence of metabolic comorbidity in individuals with severe mental illness, particularly those with schizophrenia. It highlights the increased cardiovascular risk in this population, including a reduced life expectancy and higher rates of metabolic syndrome and type 2 diabetes.<br /><br />The document emphasizes the role of psychotropic medications, particularly antipsychotics, in contributing to metabolic comorbidity in individuals with severe mental illness. It discusses the weight gain associated with antipsychotic use and the potential mechanisms behind this effect, such as alterations in hormonal dynamics and increased appetite. The document also covers the differences in weight gain risk among different antipsychotic medications.<br /><br />Various interventions for managing metabolic comorbidity in severe mental illness are discussed, including lifestyle interventions, pharmacological interventions, and behavioral interventions. The document highlights the importance of regular monitoring of weight, glucose, and lipid profiles in individuals taking psychotropic medications. It also emphasizes the need for early intervention and more intensive treatment approaches for individuals at high risk of developing cardiovascular disease.<br /><br />Additionally, the document discusses the potential benefits of metformin, a medication commonly used to treat diabetes, in managing dysglycemia in individuals with severe mental illness. The effectiveness of other pharmacological interventions, such as GLP-1 receptor agonists and lipid-lowering agents, is also examined.<br /><br />Overall, the document provides recommendations for addressing the metabolic comorbidity in severe mental illness and highlights the importance of a multidimensional approach to treatment that considers both the brain and the body.
Keywords
Metabolic comorbidity
Severe mental illness
Schizophrenia
Cardiovascular risk
Metabolic syndrome
Type 2 diabetes
Psychotropic medications
Antipsychotics
Weight gain
Interventions
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
×
Please select your language
1
English